microRNA Replacement Therapy
Press Releases

 
Press Releases
Date Title and Summary View
05-16-17 - Transaction Expected to Advance Synlogic's Innovative Platform for the Discovery and Development of Novel Synthetic Biotic™ Medicines - - Synlogic Closes $42 Million of Series C Preferred Stock Financing by Leading Biotechnology Investors - - Combined Company Well-Capitaliz...
05-09-17 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a biopharmaceutical company, today reported financial results for the first quarter of 2017 and provided a corporate update. Following its late 2016 discontinuation of all research and development activities, the Com...
03-14-17 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq: MIRN), a biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2016 and provided a corporate update. Following its November 2016 decision to discontinue all research and ...
11-10-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq: MIRN), a biopharmaceutical company focused on microRNA-based oncology therapeutics, today reported financial results for the third quarter of 2016 and provided an update on recent developments. MRX34 CLINICAL PROGRAM ...
09-20-16 Management to host conference call and webcast today at 5 p.m. Eastern AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company, today announced its decision to close the ongoing Phase 1 study of MRX34, its investigational microRNA t...
08-31-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a pipeline of microRNA-based oncology therapeutics, today announced that senior management will participate in two upcoming healthcare investor conferences in September. ...
08-15-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a pipeline of microRNA-based oncology therapeutics, today reported financial results for the second quarter of 2016 and provided an update on recent developments. ...
07-05-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced that President and Chief Executive Officer Paul Lammers, M.D., M.Sc., will present a corporate overview ...
06-30-16 AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the appointment of Perry Nisen, M.D., Ph.D., to the Company's Board of Directors. Dr. Nisen currently se...
06-06-16 Oral presentation highlights safety profile of MRX34, microRNA target engagement, and multiple clinical responses in cancer patients CHICAGO--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq: MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based ...
Page:
1
... NextLast
= add release to Briefcase
© 2017 Mirna Therapeutics, Inc. All Rights Reserved.